Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates

被引:45
作者
Hirt, Deborah [1 ,2 ]
Urien, Saik [1 ,2 ]
Rey, Elisabeth [3 ]
Arrive, Elise [4 ]
Ekouevi, Didier K. [5 ]
Coffie, Patrick [5 ]
Leang, Sim Kruy [6 ]
Lalsab, Sarita [7 ]
Avit, Divine [5 ]
Nerrienet, Eric [8 ]
McIntyre, James [7 ]
Blanche, Stephane [9 ]
Dabis, Francois [4 ]
Treluyer, Jean-Marc [1 ,2 ,3 ]
机构
[1] Univ Paris 05, EA3620, Paris, France
[2] Hop Tarnier, AP HP, Unite Rech Clin, F-75006 Paris, France
[3] Univ Paris 05, Hop Cochin St Vincent de Paul, AP HP, Serv Pharmacol Clin, Paris, France
[4] Univ Victor Segalen, INSERM, ISPED, U897, Bordeaux, France
[5] ANRS Abidjan, Programme PAC CI, Abidjan, Cote Ivoire
[6] Hop Calmette, Serv Gynecol Obstet, Phnom Penh, Cambodia
[7] Univ Witwatersrand, Chris Hani Baragwanath Hosp, Perinatal HIV Res Unit PHRU, Johannesburg, South Africa
[8] Inst Pasteur Cambodge, Phnom Penh, Cambodia
[9] Univ Paris 05, Hop Necker Enfants Malad, Serv Immunol & Hematol Pediat, Paris, France
关键词
DISOPROXIL FUMARATE; RESISTANCE; NEVIRAPINE; TENOFOVIR; QUANTIFICATION; PHARMACOLOGY;
D O I
10.1128/AAC.00860-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets-two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h(-1) (61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters.h(-1), and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg.liter(-1).h and 1.68 and 0.076 mg/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg.liter(-1). We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.
引用
收藏
页码:1067 / 1073
页数:7
相关论文
共 18 条
  • [1] [Anonymous], 15 C RETR OPP INF BO
  • [2] [Anonymous], 13 C RETR OPP INF DE
  • [3] Ways to fit a PK model with some data below the quantification limit
    Beal, SL
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (05) : 481 - 504
  • [4] Beal SL., 1998, NONMEM Users Guide
  • [5] Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers
    Blum, M. Robert
    Chittick, Gregory E.
    Begley, John A.
    Zong, Jian
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (06) : 751 - 759
  • [6] Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial
    Chi, Benjamin H.
    Sinkala, Moses
    Mbewe, Felistas
    Cantrell, Ronald A.
    Kruse, Gina
    Chintu, Namwinga
    Aldrovandi, Grace M.
    Stringer, Elizabeth M.
    Kankasa, Chipepo
    Safrit, Jeffrey T.
    Stringer, Jeffrey S. A.
    [J]. LANCET, 2007, 370 (9600) : 1698 - 1705
  • [7] Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP
    Eshleman, SH
    Hoover, DR
    Chen, S
    Hudelson, SE
    Guay, LA
    Mwatha, A
    Fiscus, SA
    Mmiro, F
    Musoke, P
    Jackson, JB
    Kumwenda, N
    Taha, T
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) : 30 - 36
  • [8] Ihaka R., 1996, J Comput Graph Stat, V5, P299, DOI [10.1080/10618600.1996.10474713, DOI 10.1080/10618600.1996.10474713, DOI 10.2307/1390807, 10.2307/1390807]
  • [9] Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
    Jackson, JB
    Becker-Pergola, G
    Guay, LA
    Musoke, P
    Mracna, M
    Fowler, MG
    Mofenson, LM
    Mirochnick, M
    Mmiro, F
    Eshleman, SH
    [J]. AIDS, 2000, 14 (11) : F111 - F115
  • [10] DRUG DISPOSITION AND PHARMACOKINETICS IN THE MATERNAL-PLACENTAL-FETAL UNIT
    KRAUER, B
    KRAUER, F
    HYTTEN, FE
    [J]. PHARMACOLOGY & THERAPEUTICS, 1980, 10 (02) : 301 - 328